Aryl pyridine as aldosterone synthase inhibitors

1. A compound of Formula (II):

or a pharmaceutically acceptable salt thereof, wherein

A is a bond, —CH 2 —, —CHR 5 — or —CR 5 R 6 —;

R 1 is C 1-7 alkyl, halo-C 1-7 alkyl, C 3-7 cycloalkyl, C 6-10 aryl, C 6-10 aryl-C 1-7 alkyl, C 6-10 aryloxy-C 1-7 alkyl, heteroaryl or heterocyclyl in which alkyl, aryl, heteroaryl, heterocyclyl are optionally substituted with 1 to 5 R 7 ;

R 2 is H, C 1-7 alkyl, halo-C 1-7 alkyl or C 3-7 cycloalkyl;

R 3 is H, halo, C 1-7 alkyl, halo-C 1-7 alkyl, C 3-7 cycloalkyl, cyano, C 1-7 alkoxy, hydroxy, nitro, —NH 2 , —NH(C 1-7 alkyl) or —N(C 1-7 alkyl) 2 ;

each R 4 is independently selected from the group consisting of halo, C 1-7 alkyl, halo-C 1-7 alkyl, C 3-7 cycloalkyl, cyano, —NH 2 , —NH(C 1-7 alkyl), —N(C 7-7 alkyl) 2 , C 1-7 alkoxy, halo-C 1-7 alkoxy, hydroxy, carboxy, nitro, sulfonyl, sulfamoyl, sulfonamido, C 6-10 aryl, heterocyclyl, C 6-70 aryloxy, heterocyclyloxy, —SH, —S—C 1-7 alkyl, —C(O)O-aryl, —C(O)O-heterocyclyl, —C(O)O-heteroaryl, —C(O)NR 2 — C 1-7 alkyl, —C(O)NR 2 —C 6-10 aryl, —C(O)NR 2 -heteroaryl, —C(O)NR 2 -heterocyclyl, —NR 2 C(O)—C 1-7 alkyl, —NR 2 C(O)—C 6-10 aryl, —NR 2 C(O)-heteroaryl, —NR 2 C(O)-heterocyclyl, —OC(O)—C 1-7 alkyl, —OC(O)—C 6-10 aryl, —OC(O)-heteroaryl and —OC(O)-heterocyclyl; wherein R 4 is optionally substituted with 1 to 5 R 7 ;

R 5 and R 6 are independently C 1-7 alkyl, C 3-7 cycloalkyl, halo-C 1-7 alkyl, heterocyclyl;

each R 7 is independently selected from the group consisting of halo, C 1-7 alkyl, C 3-7 cycloalkyl, C 1-7 alkoxy, C 6-10 aryloxy, heterocyclyl, C 6-10 aryl, heteroaryl, CN and halo-C 1-7 alkyl;

p is 0, 1, 2, 3, 4 or 5; and the compound of Formula I is not 2-methyl-N-(6-(5-(phenylsulfonamido)pyridin-3-yl)-1H-indazol-4-yl)thiazole-4-carboxamide, 2-chloro-N-isobutyl-N-((5-(3-(methylsulfonyl)phenyl)pyridin-3-yl)methyl)benzenesulfonamide or 4-(5-(4-chloro-2,5-dimethylphenylsulfonamido)pyridin-3-yl)benzoic acid.

2. The compound of claim 1 having Formula (III):

or a pharmaceutically acceptable salt thereof, wherein C is phenyl, and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and p are as defined in claim 1 .

3. The compound of claim 1 having formula (IV):

or a pharmaceutically acceptable salt thereof, wherein C is phenyl, and R 1 , R 2 , R 3 , R 4 and p are as defined in claim 1 .

4. The compound of claim 1 having Formula (V):

or a pharmaceutically acceptable salt thereof, wherein C is phenyl, and R 1 , R 2 , R 3 , R 4 , R 5a , R 6a , R 5b , R 6b and p are as defined in claim 1 .

5. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is independently selected from C 1-4 alkyl, C 1-4 alkoxy, CN, halo, halo-C 1-4 alkyl or halo-C 1-7 alkoxy.

6. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is CHR 5 .

7. The compound of claim 1 , or a pharmaceutically salt thereof wherein R 1 is C 1-4 alkyl, R 2 is H, R 3 is H, A is CHR 5 , R 5 is C 1-4 alkyl or C 3-6 cycloalkyl, p is 1 or 2; and each R 4 is independently C 1-4 alkyl, halo-C 1-4 alkyl, C 1-4 alkoxy, CN, halo or halo-C 1-4 alkoxy.

8. The compound of claim 1 selected from the group consisting of:

N-(5-(3-chloro-4-cyanophenyl)pyridin-3-yl)ethanesulfonamide;

N-[5-(3-Chloro-4-cyano-phenyl)-pyridin-3-yl]-4-methoxy-benzene-sulfonamide;

N-[5-(3-Chloro-4-cyano-phenyl)-pyridin-3-yl]-4-fluoro-benzene-sulfonamide;

N-[5-(3-Chloro-4-cyano-phenyl)-pyridin-3-yl]-4-ethyl-benzene-sulfonamide;

N-[5-(3-Chloro-4-cyano-phenyl)-pyridin-3-yl]-4-cyano-benzene-sulfonamide;

N-[5-(3-Chloro-4-cyano-phenyl)-pyridin-3-yl]-4-trifluoromethyl-benzenesulfonamide;

N-[5-(3-Chloro-4-cyano-phenyl)-pyridin-3-yl]-4-fluoro-2-methyl-benzenesulfonamide;

N-(5-(3-chloro-4-cyanophenyl)pyridin-3-yl)-2,2,2-trifluoromethanesulfonamide;

N-[5-(3-Chloro-4-cyano-phenyl)-pyridin-3-yl]-1-phenyl-methanesulfonamide;

N-(5-(3-chloro-4-cyanophenyl)pyridin-3-yl)-2-phenoxyethanesulfonamide;

N-[5-(3-Chloro-4-cyano-phenyl)-pyridin-3-yl]-4-methyl-benzenesulfonamide;

N-(5-(3-chloro-4-cyanophenyl)pyridin-3-yl)-1-(2-chlorophenyl)methanesulfonamide;

N-(5-(3-chloro-4-cyanophenyl)pyridin-3-yl)-1-(4-fluorophenyl)methanesulfonamide;

Cyclopropanesulfonic acid [5-(3-chloro-4-cyano-phenyl)-pyridin-3-yl]amide;

N-(5-(3-chloro-4-cyanophenyl)pyridin-3-yl)propane-1-sulfonamide;

N-(5-(3-chloro-4-cyanophenyl)pyridin-3-yl)butane-1-sulfonamide;

N-(5-(4-cyano-3-methoxyphenyl)pyridin-3-yl)-2,2,2-trifluoromethanesulfonamide;

N-(5-(4-cyano-3-methoxyphenyl)pyridin-3-yl)ethanesulfonamide; N-(5-(4-cyano-3-methoxyphenyl)pyridin-3-yl)cyclopropane-sulfonamide;

N-((5-(4-cyano-3-methoxyphenyl)pyridin-3-yl)methyl)methane-sulfonamide;

N-((5-(4-cyano-3-methoxyphenyl)pyridin-3-yl)ethyl)ethanesulfonamide;

N-((5-(4-cyano-3-methoxyphenyl)pyridin-3-yl)methyl)-1,1,1-trifluoromethanesulfonamide; N-((5-(3-chloro-4-cyanophenyl)pyridin-3-yl)methyl)ethanesulfonamide;

N-((5-(4-cyano-3-ethoxyphenyl)pyridin-3-yl)methyl)ethanesulfonamide;

N-(1-(5-(3-chloro-4-cyanophenyl)pyridin-3-yl)-2-methylpropyl)ethanesulfonamide;

N-(1-(5-(4-cyano-3-methoxyphenyl)pyridin-3-yl)ethyl)ethanesulfonamide;

N-(1-(5-(3-chloro-4-cyanophenyl)pyridin-3-yl)ethyl)ethanesulfonamide;

N-(1-(5-(3-chloro-4-cyanophenyl)pyridin-3-yl)butyl)ethanesulfonamide;

(R)—N-((5-(3-chloro-4-cyanophenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide;

(S)—N-((5-(3-chloro-4-cyanophenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide;

N-((5-(3-chloro-4-cyanophenyl)pyridin-3-yl)(cyclopropyl)methyl)methanesulfonamide;

N-((5-(4-cyano-3-methoxyphenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide;

(S)—N-((5-(4-cyano-2-methoxyphenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide;

(R)—N-((5-(4-cyano-2-methoxyphenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide

(R)—N-((5-(4-cyano-3-fluorophenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide;

(S)—N-((5-(4-cyano-3-fluorophenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide

N-((5-(4-cyano-2-fluorophenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide;

N-((5-(3-chloro-4-cyanophenyl)pyridin-3-yl)(cyclopentyl)methyl)ethanesulfonamide;

N-((5-(3-chloro-4-cyanophenyl)pyridin-3-yl)(cyclopropyl)methyl)propane-2-sulfonamide; N-(cyclopropyl(5-(2-methoxyphenyl)pyridin-3-yl)methyl)ethanesulfonamide;

N-((5-(2-chlorophenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide;

N-((5-(4-cyanophenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide;

N-(2-(5-(3-chloro-4-cyanophenyl)pyridin-3-yl)propan-2-yl)ethanesulfonamide;

N-(cyclopropyl(5-(3-fluorophenyl)pyridin-3-yl)methyl)ethanesulfonamide;

N-(cyclopropyl(5-(4-methoxyphenyl)pyridin-3-yl)methyl)ethanesulfonamide;

N-(cyclopropyl(5-(4-ethoxyphenyl)pyridin-3-yl)methyl)ethanesulfonamide;

N-((5-(3-chlorophenyl)pyridin-3-yl)(cyclopropyl)methyl)-ethanesulfonamide;

N-(cyclopropyl(5-(4-fluorophenyl)pyridin-3-yl)methyl)ethanesulfonamide;

N-(cyclopropyl(5-(2,4-dichlorophenyl)pyridin-3-yl)methyl)ethanesulfonamide;

N-(cyclopropyl(5-(3,5-dimethylphenyl)pyridin-3-yl)methyl)ethanesulfonamide;

N-(cyclopropyl(5-(3,5-dichlorophenyl)pyridin-3-yl)methyl)ethanesulfonamide;

N-((5-(4-chlorophenyl)pyridin-3-yl)(cyclopropyl)methyl)-ethanesulfonamide;

N-(cyclopropyl(5-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)methyl)ethanesulfonamide;

N-(cyclopropyl(5-(2,3-dichlorophenyl)pyridin-3-yl)methyl)ethanesulfonamide;

N-((5-(3-chloro-4-fluorophenyl)pyridin-3-yl)(cyclopropyl)methyl)-ethanesulfonamide;

N-((5-(3-chloro-4-cyanophenyl)pyridin-3-yl)(cyclopropyl)methyl)-N-methylethanesulfonamide;

N-(cyclopropyl(5-(4-fluoro-3-methyl-phenyl)pyridin-3-yl)methyl)ethanesulfonamide;

N-(cyclopropyl(5-(4-ethylsulfanyl-phenyl)pyridin-3-yl)methyl)ethanesulfonamide;

N-(cyclopropyl(5-(3-fluoro-4-methoxy-phenyl)pyridin-3-yl)methyl)ethanesulfonamide;

N-(cyclopropyl(5-(2,4-dimethoxy-phenyl)pyridin-3-yl)methyl)ethanesulfonamide;

N-(cyclopropyl(5-(4-methylsulfanyl-phenyl)pyridin-3-yl)methyl)ethanesulfonamide;

Ethanesulfonic acid {[5-(3-chloro-4-cyano-phenyl)-pyridin-3-yl]-cyclopropyl-methyl}-ethyl-amide;

Ethanesulfonic acid {[5-(3-chloro-4-cyano-phenyl)-pyridin-3-yl]-cyclopropyl-methyl}-(3-methyl-butyl)-amide;

({[5-(3-Chloro-4-cyano-phenyl)-pyridin-3-yl]cyclopropyl-methyl}-ethanesulfonyl-amino)-acetic acid methyl ester;

Ethanesulfonic acid {[5-(3-chloro-4-cyano-phenyl)-pyridin-3-yl]-cyclopropyl-methyl}-isobutyl-amide;

Ethanesulfonic acid {[5-(3-chloro-4-cyano-phenyl)-pyridin-3-yl]-cyclopropyl-methyl}-(2-hydroxy-ethyl)-amide;

N-(1-(5-(3-chloro-4-cyanophenyl)pyridin-3-yl)cyclopropyl)ethane-sulfonamide;

N-((4-chloro-5-(3-chloro-4-cyanophenyl)pyridin-3-yl)(cyclopropyl)methyl)-N-methylmethanesulfonamide;

(R)—N-((5-(4-cyano-3-methylphenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide;

(S)—N-((5-(4-cyano-3-methylphenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide;

N-((5-(4-cyano-3-methylphenyl)pyridin-3-yl)(4-fluorophenyl)methyl)ethane-sulfonamide;

N-(1-(5-(4-cyano-3-methylphenyl)pyridin-3-yl)-2,2,2-trifluoroethyl)ethane-sulfonamide;

N-(2-(5-(2,3-dichlorophenyl)pyridin-3-yl)ethyl)ethanesulfonamide; and

N-(2-(5-(2,3-dichlorophenyl)pyridin-3-yl)cyclopropyl)ethane-sulfonamide; or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

10. A pharmaceutical combination, comprising a therapeutically effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and one or more therapeutically active agents selected from the group consisting of an HMG-Co-A reductase inhibitor, an angiotensin II receptor antagonist, angiotensin converting enzyme (ACE) Inhibitor, a calcium channel blocker (CCB), a dual angiotensin converting enzyme/neutral endopeptidase (ACE/NEP) inhibitor, an endothelin antagonist, a renin inhibitor, a diuretic, an ApoA-I mimic, an anti-diabetic agent, an obesity-reducing agent, an aldosterone receptor blocker, an endothelin receptor blocker, and a CETP inhibitor.

11. A method of inhibiting aldosterone synthase activity in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

12. A method of treating a disorder or a disease in a subject mediated by aldosterone synthase, comprising: administering to the subject a therapeutically effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein the disorder or the disease is selected from the group consisting of hypokalemia, hypertension, Conn's disease, renal failure, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collagen, fibrosis and remodeling following hypertension and endothelial dysfunction, cardiovascular diseases, renal dysfunction, liver diseases, cerebrovascular diseases, vascular diseases, retinopathy, neuropathy, insulinopathy, edema, endothelial dysfunction, baroreceptor dysfunction, migraine headaches, heart failure, arrhythmia, diastolic dysfunction, left ventricular diastolic dysfunction, diastolic heart failure, impaired diastolic filling, systolic dysfunction, ischemia, hypertrophic cardiomyopathy, sudden cardiac death, myocardial and vascular fibrosis, impaired arterial compliance, myocardial necrotic lesions, vascular damage, myocardial infarction, left ventricular hypertrophy, decreased ejection fraction, cardiac lesions, vascular wall hypertrophy, endothelial thickening, and fibrinoid necrosis of coronary arteries.

13. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 7 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

14. A method of treating a disorder or a disease in a subject mediated by aldosterone synthase, wherein the disorder or the disease is selected from the group consisting of hypokalemia, hypertension, Conn's disease, renal failure, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collagen, fibrosis and remodeling following hypertension and endothelial dysfunction, cardiovascular diseases, renal dysfunction, liver diseases, cerebrovascular diseases, vascular diseases, retinopathy, neuropathy, insulinopathy, edema, endothelial dysfunction, baroreceptor dysfunction, migraine headaches, heart failure, arrhythmia, diastolic dysfunction, left ventricular diastolic dysfunction, diastolic heart failure, impaired diastolic filling, systolic dysfunction, ischemia, hypertrophic cardiomyopathy, sudden cardiac death, myocardial and vascular fibrosis, impaired arterial compliance, myocardial necrotic lesions, vascular damage, myocardial infarction, left ventricular hypertrophy, decreased ejection fraction, cardiac lesions, vascular wall hypertrophy, endothelial thickening, and fibrinoid necrosis of coronary arteries comprising:

administering to the subject a therapeutically effective amount of the compound according to claim 7 or a pharmaceutically acceptable salt thereof.